Clinical trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma
10 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 1NCT06856499Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerUniversity of Colorado, Denver · PI: Bradley Corr
- RECRUITINGPhase 3NCT06994195A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian CancerSichuan Baili Pharmaceutical Co., Ltd.
- RECRUITINGPhase 2NCT07024784A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesAbbVie · PI: ABBVIE INC.
- RECRUITINGN/ANCT06969833Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube CarcinomaCentre Oscar Lambret
- RECRUITINGPhase 3NCT05659381Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube CancerGOG Foundation · PI: Leslie Randall, MD
- RECRUITINGN/ANCT05597683Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal ChemotherapyGangnam Severance Hospital · PI: Young Song
- ACTIVE NOT RECRUITINGPhase 2NCT05456685Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerAbbVie · PI: ABBVIE INC.
- RECRUITINGPhase 3NCT05281471Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)Genelux Corporation · PI: Robert W. Holloway, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05406674Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian CancerThe Netherlands Cancer Institute · PI: W. van Driel, MD PhD
- ACTIVE NOT RECRUITINGNCT06839157Artificial Intelligence - Assisted Model for Optimal Timing of Surgery in Advanced Ovarian CancerShanghai Gynecologic Oncology Group